NPPA fixes retail price of 68 drug formulations

Drug price regulator NPPA Friday fixed prices as well as revised ceiling and retail prices of 68 formulations, including those used for treatment of diabetes, blood pressure and HIV. The National Pharmaceutical Pricing Authority (NPPA) said while the retail price of 55 scheduled formulations has been fixed, that of 10 has been revised. Further, the authority has also fixed ceiling prices of three scheduled formulations.

“NPPA has fixed/revised ceiling prices/retail prices of 68 formulations under Drugs (Prices Control) Order, 2013,” it said in a notification.

NPPA fixes the ceiling price of essential medicines of Schedule I under the Drugs (Prices Control) Order (DPCO) 2013. In respect of medicines that are not under price control, manufacturers are allowed to increase the maximum retail price by 10 per cent annually.

The calculation for essential drugs is based on the simple average of all the medicines in a particular therapeutic segment with sales of more than 1 per cent.

Set up in 1997, the NPPA has been entrusted with the task of fixation/revision of prices of pharma products, enforcement of provisions of DPCO and monitoring of prices of controlled and decontrolled drugs.

  • Related Posts

    PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

    PharmEasy, the online medical platform emphasizes the importance of early prevention and regular health screenings to reduce the risk of diabetes. By encouraging individuals to undergo timely blood sugar tests,…

    Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

    India’s pharmaceutical exporters have been offered a fresh business opportunity to expand their presence in Saudi Arabia, with Riyadh-based Al Hobail Medical Company seeking Indian manufacturing partners for the registration…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

    PharmEasy sees need for early prevention and regular screening to stall risk of diabetes

    Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

    Saudi pharma company seeks Indian manufacturers for product registration, commercialisation in Saudi Arabia

    From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

    From ‘Kidney Care’ to ‘Liver Detox’, Uttar Pradesh bans misleading supplement labels

    UP expands food, drug testing capacity across all 18 divisions

    UP expands food, drug testing capacity across all 18 divisions

    Abbott receives US FDA approval and CE Mark for the UltiSynq defibrillation lead

    Abbott receives US FDA approval and CE Mark for the UltiSynq defibrillation lead

    Medicines worth ₹14 lakh seized from unlicensed residential premises in Delhi

    Medicines worth ₹14 lakh seized from unlicensed residential premises in Delhi